about
Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.Ileal pouch-anal anastomosis for ulcerative colitis: a Canadian institution's experience.Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal Anastomosis.Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.Modified Two-stage Ileal Pouch-Anal Anastomosis Results in Lower Rate of Anastomotic Leak Compared with Traditional Two-stage Surgery for Ulcerative Colitis.Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease.Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.High frequency of vitamin B12 deficiency in asymptomatic individuals homozygous to MTHFR C677T mutation is associated with endothelial dysfunction and homocysteinemiaAssociation of Vitamin B12 Deficiency with Homozygosity of the TT MTHFR C677T Genotype, Hyperhomocysteinemia, and Endothelial Cell DysfunctionPreoperative exposure to anti-tumor necrosis factor therapy in ulcerative colitis patients undergoing ileal pouch-anal anastomosis (IPAA) is not associated with histological fibrosis: A case control studyFecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activityPreoperative Exclusive Total Parental Nutrition is Associated with Clinical and Laboratory Remission in Severe Active Crohn's Disease-A Pilot StudyEffectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
P50
Q38702414-E982A900-70BE-4523-A475-3B748A9566E8Q38972435-526BC422-353A-4979-8023-8B34AC325288Q39410539-3C423DDB-B041-4916-8C03-A28982A4670BQ40038096-6F69B1E3-5F27-4A00-A208-F4333747502BQ40867447-8578D600-4B86-44CD-B6E5-1055B8FF2E11Q51029746-1030962B-1CD9-49C0-97B2-6805F0A093F4Q54530445-FDB65675-C28B-4FEC-8CA5-13FC9E846676Q80194731-5EBADB6A-D31F-4A1A-8B40-5B376BA6A9D6Q85517309-120DAADD-F95D-40E1-B20F-7C9E5AA41DE9Q92706786-0BE69350-3D6B-47AB-9B24-3B76854F5485Q93355882-16CA7D41-A57C-44A8-ABE5-5D157532002EQ94470782-7730F20C-4FA5-4AD8-B3D4-0F2A7498EFCCQ94930175-8068F905-4013-4625-AB0B-19D034627937
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eran Zittan
@ast
Eran Zittan
@en
Eran Zittan
@es
Eran Zittan
@nl
Eran Zittan
@sl
type
label
Eran Zittan
@ast
Eran Zittan
@en
Eran Zittan
@es
Eran Zittan
@nl
Eran Zittan
@sl
prefLabel
Eran Zittan
@ast
Eran Zittan
@en
Eran Zittan
@es
Eran Zittan
@nl
Eran Zittan
@sl
P106
P21
P31
P496
0000-0003-3378-4932
P569
2000-01-01T00:00:00Z